These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30384269)

  • 41. Amoebicidal activities of alexidine against 3 pathogenic strains of acanthamoeba.
    Alizadeh H; Neelam S; Cavanagh HD
    Eye Contact Lens; 2009 Jan; 35(1):1-5. PubMed ID: 19125040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp.
    Mrva M; Garajová M; Lukáč M; Ondriska F
    J Parasitol; 2011 Jun; 97(3):538-40. PubMed ID: 21506779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of surface charge on the size-dependent cellular internalization of liposomes.
    Sakai-Kato K; Yoshida K; Izutsu KI
    Chem Phys Lipids; 2019 Nov; 224():104726. PubMed ID: 30660745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of propolis in experimental Acanthamoeba keratitis.
    Vural A; Polat ZA; Topalkara A; Toker MI; Erdogan H; Arici MK; Cetin A
    Clin Exp Ophthalmol; 2007 Nov; 35(8):749-54. PubMed ID: 17997780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crosslinking and corneal cryotherapy in acanthamoeba keratitis -- a histological study.
    Hager T; Hasenfus A; Stachon T; Seitz B; Szentmáry N
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):149-53. PubMed ID: 26483144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acanthamoeba keratitis in Mexico: Report of a clinical case and importance of sensitivity assays for a better outcome.
    Omaña-Molina M; Vanzzini-Zago V; Hernández-Martínez D; Reyes-Batlle M; Castelan-Ramírez I; Hernández-Olmos P; Salazar-Villatoro L; González-Robles A; Ramírez-Flores E; Servín-Flores C; Flores-Alvarado V; Alcántara-Castro M; Lorenzo-Morales J
    Exp Parasitol; 2019 Jan; 196():22-27. PubMed ID: 30472333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro development of an effective treatment for Acanthamoeba keratitis.
    Ortillés Á; Belloc J; Rubio E; Fernández MT; Benito M; Cristóbal JÁ; Calvo B; Goñi P
    Int J Antimicrob Agents; 2017 Sep; 50(3):325-333. PubMed ID: 28709990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery.
    Podesta JE; Kostarelos K
    Methods Enzymol; 2009; 464():343-54. PubMed ID: 19903563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autophagy inhibitors as a potential antiamoebic treatment for Acanthamoeba keratitis.
    Moon EK; Kim SH; Hong Y; Chung DI; Goo YK; Kong HH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4020-5. PubMed ID: 25896709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnosis and management of Acanthamoeba keratitis.
    McCulley JP; Alizadeh H; Niederkorn JY
    CLAO J; 2000 Jan; 26(1):47-51. PubMed ID: 10656311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro corneal pathogenicity of Acanthamoeba.
    Larkin DF; Berry M; Easty DL
    Eye (Lond); 1991; 5 ( Pt 5)():560-8. PubMed ID: 1794422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and in vitro activity of new biguanide-containing dendrimers on pathogenic isolates of Acanthamoeba polyphaga and Acanthamoeba griffini.
    Martín-Pérez T; Lozano-Cruz T; Criado-Fornelio A; Ortega P; Gómez R; de la Mata FJ; Pérez-Serrano J
    Parasitol Res; 2019 Jun; 118(6):1953-1961. PubMed ID: 31069536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of lactoferrin on the viability and the encystment of Acanthamoeba trophozoites.
    Tomita S; Suzuki C; Wada H; Nomachi M; Imayasu M; Araki-Sasaki K
    Biochem Cell Biol; 2017 Feb; 95(1):48-52. PubMed ID: 28140621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
    Vasseneix C; Gargala G; François A; Hellot MF; Duclos C; Muraine M; Benichou J; Ballet JJ; Brasseur G; Favennec L
    Cornea; 2006 Jun; 25(5):597-602. PubMed ID: 16783150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanoparticles based therapeutic efficacy against Acanthamoeba: Updates and future prospect.
    Sharma G; Kalra SK; Tejan N; Ghoshal U
    Exp Parasitol; 2020 Nov; 218():108008. PubMed ID: 32979343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.
    Narasimhan S; Madhavan HN; K LT
    Cornea; 2002 Mar; 21(2):203-5. PubMed ID: 11862096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acanthamoeba keratitis with two species of Acanthamoeba.
    Beattie AM; Slomovic AR; Rootman DS; Hunter WS
    Can J Ophthalmol; 1990 Aug; 25(5):260-2. PubMed ID: 2207874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acanthamoeba keratitis: persistent organisms without inflammation after 1 year of topical chlorhexidine.
    Gooi P; Lee-Wing M; Brownstein S; El-Defrawy S; Jackson WB; Mintsioulis G
    Cornea; 2008 Feb; 27(2):246-8. PubMed ID: 18216589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization and pathogenic potential of a soil isolate and an ocular isolate of Acanthamoeba castellanii in relation to Acanthamoeba keratitis.
    van Klink F; Alizadeh H; Stewart GL; Pidherney MS; Silvany RE; He Y; McCulley JP; Niederkorn JY
    Curr Eye Res; 1992 Dec; 11(12):1207-20. PubMed ID: 1490339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of morphological and electrophysiological changes in hamster cornea after in vitro interaction with trophozoites of Acanthamoeba spp.
    Omaña-Molina M; Navarro-García F; González-Robles A; Serrano-Luna Jde J; Campos-Rodríguez R; Martínez-Palomo A; Tsutsumi V; Shibayama M
    Infect Immun; 2004 Jun; 72(6):3245-51. PubMed ID: 15155626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.